SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 9th, 2024 • Alzamend Neuro, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 9th, 2024 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is entered into and effective as of May 8, 2024 (the “Execution Date”), by and between Alzamend Neuro, Inc., a Delaware corporation (the “Company”) and Orchid Finance LLC, a Nevada limited liability company (including its designees, successors and assigns, the “Purchaser”).
ContractAlzamend Neuro, Inc. • May 9th, 2024 • Pharmaceutical preparations
Company FiledMay 9th, 2024 IndustryAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 9th, 2024 • Alzamend Neuro, Inc. • Pharmaceutical preparations
Contract Type FiledMay 9th, 2024 Company IndustryThis Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and the Purchaser (the “Purchase Agreement”).